These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
319 related articles for article (PubMed ID: 17660026)
1. Mycophenolate mofetil in idiopathic membranous nephropathy: a clinical trial with comparison to a historic control group treated with cyclophosphamide. Branten AJ; du Buf-Vereijken PW; Vervloet M; Wetzels JF Am J Kidney Dis; 2007 Aug; 50(2):248-56. PubMed ID: 17660026 [TBL] [Abstract][Full Text] [Related]
2. Mycophenolate mofetil monotherapy in membranous nephropathy: a 1-year randomized controlled trial. Dussol B; Morange S; Burtey S; Indreies M; Cassuto E; Mourad G; Villar E; Pouteil-Noble C; Karaaslan H; Sichez H; Lasseur C; Delmas Y; Nogier MB; Fathallah M; Loundou A; Mayor V; Berland Y Am J Kidney Dis; 2008 Oct; 52(4):699-705. PubMed ID: 18585835 [TBL] [Abstract][Full Text] [Related]
3. Comparison of different therapies in high-risk patients with idiopathic membranous nephropathy. Peng L; Wei SY; Li LT; He YX; Li B J Formos Med Assoc; 2016 Jan; 115(1):11-8. PubMed ID: 26315481 [TBL] [Abstract][Full Text] [Related]
4. Reduction of proteinuria with mycophenolate mofetil in predominantly membranous lupus nephropathy. Karim MY; Pisoni CN; Ferro L; Tungekar MF; Abbs IC; D'Cruz DP; Khamashta MA; Hughes GR Rheumatology (Oxford); 2005 Oct; 44(10):1317-21. PubMed ID: 16049051 [TBL] [Abstract][Full Text] [Related]
5. Short- and long-term efficacy of oral cyclophosphamide and steroids in patients with membranous nephropathy and renal insufficiency. Study Group. Branten AJ; Wetzels JF Clin Nephrol; 2001 Jul; 56(1):1-9. PubMed ID: 11499653 [TBL] [Abstract][Full Text] [Related]
7. Mycophenolate mofetil or standard therapy for membranous nephropathy and focal segmental glomerulosclerosis: a pilot study. Senthil Nayagam L; Ganguli A; Rathi M; Kohli HS; Gupta KL; Joshi K; Sakhuja V; Jha V Nephrol Dial Transplant; 2008 Jun; 23(6):1926-30. PubMed ID: 17989103 [TBL] [Abstract][Full Text] [Related]
8. The Effect of Mycophenolate Mofetil versus Cyclosporine as Combination Therapy with Low Dose Corticosteroids in High-risk Patients with Idiopathic Membranous Nephropathy: a Multicenter Randomized Trial. Choi JY; Kim DK; Kim YW; Yoo TH; Lee JP; Chung HC; Cho KH; An WS; Lee DH; Jung HY; Cho JH; Kim CD; Kim YL; Park SH J Korean Med Sci; 2018 Feb; 33(9):e74. PubMed ID: 29441742 [TBL] [Abstract][Full Text] [Related]
9. Cytotoxic therapy for membranous nephropathy and renal insufficiency: improved renal survival but high relapse rate. du Buf-Vereijken PW; Branten AJ; Wetzels JF; Nephrol Dial Transplant; 2004 May; 19(5):1142-8. PubMed ID: 14993502 [TBL] [Abstract][Full Text] [Related]
10. Mycophenolate Mofetil Combined With Prednisone Versus Full-Dose Prednisone in IgA Nephropathy With Active Proliferative Lesions: A Randomized Controlled Trial. Hou JH; Le WB; Chen N; Wang WM; Liu ZS; Liu D; Chen JH; Tian J; Fu P; Hu ZX; Zeng CH; Liang SS; Zhou ML; Zhang HT; Liu ZH Am J Kidney Dis; 2017 Jun; 69(6):788-795. PubMed ID: 28215945 [TBL] [Abstract][Full Text] [Related]
11. Mycophenolate mofetil versus cyclophosphamide for inducing remission of ANCA vasculitis with moderate renal involvement. Hu W; Liu C; Xie H; Chen H; Liu Z; Li L Nephrol Dial Transplant; 2008 Apr; 23(4):1307-12. PubMed ID: 18065810 [TBL] [Abstract][Full Text] [Related]
12. Mycophenolate Mofetil with Steroid, a Reasonable Alternative to Current First-line Therapy, for Idiopathic Membranous Nephropathy in Resource-constrained Settings: A Randomized, Open-label Study. Sharma M; Roy A; Doley PK; Pegu G J Assoc Physicians India; 2024 Jun; 72(6):15-19. PubMed ID: 38881128 [TBL] [Abstract][Full Text] [Related]
13. Use of mycophenolate mofetil in resistant membranous nephropathy. Miller G; Zimmerman R; Radhakrishnan J; Appel G Am J Kidney Dis; 2000 Aug; 36(2):250-6. PubMed ID: 10922302 [TBL] [Abstract][Full Text] [Related]
14. Prospective controlled study on mycophenolate mofetil and prednisolone in the treatment of membranous nephropathy with nephrotic syndrome. Chan TM; Lin AW; Tang SC; Qian JQ; Lam MF; Ho YW; Tse KC; Chan KW; Lai KN; Tang CS Nephrology (Carlton); 2007 Dec; 12(6):576-81. PubMed ID: 17995584 [TBL] [Abstract][Full Text] [Related]
15. Association of anti-PLA₂R antibodies with outcomes after immunosuppressive therapy in idiopathic membranous nephropathy. Bech AP; Hofstra JM; Brenchley PE; Wetzels JF Clin J Am Soc Nephrol; 2014 Aug; 9(8):1386-92. PubMed ID: 25035272 [TBL] [Abstract][Full Text] [Related]
16. [A randomized control trial of mycophenolate mofeil treatment in severe IgA nephropathy]. Chen X; Chen P; Cai G; Wu J; Cui Y; Zhang Y; Liu S; Tang L Zhonghua Yi Xue Za Zhi; 2002 Jun; 82(12):796-801. PubMed ID: 12126522 [TBL] [Abstract][Full Text] [Related]
17. Sustained remission of membranous glomerulonephritis after cyclophosphamide and prednisone. Bruns FJ; Adler S; Fraley DS; Segel DP Ann Intern Med; 1991 May; 114(9):725-30. PubMed ID: 2012353 [TBL] [Abstract][Full Text] [Related]
18. Treatment of idiopathic membranous nephropathy with the combination of steroids, tacrolimus and mycophenolate mofetil: results of a pilot study. Ballarin J; Poveda R; Ara J; Pérez L; Calero F; Grinyó JM; Romero R Nephrol Dial Transplant; 2007 Nov; 22(11):3196-201. PubMed ID: 17595183 [TBL] [Abstract][Full Text] [Related]
19. Mycophenolate mofetil or intravenous cyclophosphamide for lupus nephritis with poor kidney function: a subgroup analysis of the Aspreva Lupus Management Study. Walsh M; Solomons N; Lisk L; Jayne DR Am J Kidney Dis; 2013 May; 61(5):710-5. PubMed ID: 23375819 [TBL] [Abstract][Full Text] [Related]
20. A comparison of a standard-dose prednisone regimen and mycophenolate mofetil combined with a lower prednisone dose in Chinese adults with idiopathic nephrotic syndrome who were carriers of hepatitis B surface antigen: a prospective cohort study. Li X; Tian J; Wu J; He Q; Li H; Han F; Li Q; Chen Y; Ni Q; Chen J Clin Ther; 2009 Apr; 31(4):741-50. PubMed ID: 19446147 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]